Myalept

MYALEPT- metreleptin injection, powder, lyophilized, for solution
Amryt Pharmaceuticals DAC

WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF LYMPHOMA

Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of endogenous leptin action and/or loss of MYALEPT efficacy. Severe infection and/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of MYALEPT efficacy during treatment. Contact Amryt Pharmaceuticals DAC at 1-866-216-1526 for neutralizing antibody testing of clinical samples [see Contraindications (4.1) and Warnings and Precautions (5.1)].

T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with MYALEPT. Carefully consider the benefits and risks of treatment with MYALEPT in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy [see Warnings and Precautions (5.2)].

Because of these risks associated with the development of anti-metreleptin antibodies that neutralize endogenous leptin and/or MYALEPT and the risk for lymphoma, MYALEPT is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYALEPT REMS PROGRAM [see Warnings and Precautions (5.3)].

1 INDICATIONS AND USAGE

1.1 Patients with Generalized Lipodystrophy

MYALEPT (metreleptin) for injection is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Limitations of Use

  • The safety and effectiveness of MYALEPT for the treatment of complications of partial lipodystrophy have not been established.
  • The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established.
  • MYALEPT is not indicated for use in patients with HIV-related lipodystrophy.
  • MYALEPT is not indicated for use in patients with metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent evidence of congenital or acquired generalized lipodystrophy.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

See Table 1 for the recommended daily dose and maximum recommended daily dose in adults and pediatric patients.

Based on clinical response (e.g., inadequate metabolic control) or other considerations (e.g., tolerability issues, excessive weight loss [especially in pediatric patients]), MYALEPT dosage may be decreased or increased to the maximum dosage listed in Table 1.

Table 1: MYALEPT Recommended Dosage
Baseline weight Starting daily dose (injection volume) Dose adjustments (injection volume) Maximum daily dose (injection volume)

Less than or equal to 40 kg(males and females)

0.06 mg/kg(0.012 mL/kg)

0.02 mg/kg(0.004 mL/kg)

0.13 mg/kg(0.026 mL/kg)

Males greater than 40 kg

2.5 mg(0.5 mL)

1.25 mg (0.25 mL) to2.5 mg (0.5 mL)

10 mg(2 mL)

Females greater than 40 kg

5 mg (1 mL)

1.25 mg (0.25 mL) to2.5 mg (0.5 mL)

10 mg(2 mL)

In pediatric patients, small volumes for administration can result in medication errors when measured incorrectly [see Dosage and Administration (2.3), Adverse Reactions (6.3)]. Table 2 provides example doses and volumes by weight. For patients using insulin syringes, the volume conversion is 100 Units/mL.

Table 2: Example Dosing Chart for Patients Less than or Equal to 40 kg
Weight Starting Dose Dose Adjustment Maximum Dose
5 kg 0.30 mg (0.06 mL or 6 Units) 0.10 mg (0.02 mL or 2 Units) 0.65 mg (0.13 mL or 13 Units)
10 kg 0.60 mg (0.12 mL or 12 Units) 0.20 mg (0.04 mL or 4 Units) 1.3 mg (0.26 mL or 26 Units)
15 kg 0.90 mg (0.18 mL or 18 Units) 0.30 mg (0.06 mL or 6 Units) 1.95 mg (0.39 mL or 39 Units)
20 kg 1.2 mg (0.24 mL or 24 Units) 0.40 mg (0.08 mL or 8 Units) 2.6 mg (0.52 mL or 52 Units)
25 kg 1.5 mg (0.3 mL or 30 Units) 0.50 mg (0.1 mL or 10 Units) 3.25 mg (0.65 mL or 65 Units)
30 kg 1.8 mg (0.36 mL or 36 Units) 0.60 mg (0.12 mL or 12 Units) 3.9 mg (0.78 mL or 78 Units)
35 kg 2.1 mg (0.42 mL or 42 Units) 0.70 mg (0.14 mL or 14 Units) 4.55 mg (0.91 mL or 91 Units)
40 kg 2.4 mg (0.48 mL or 48 Units) 0.80 mg (0.16 mL or 16 Units) 5.2 mg (1.03 mL or 103 Units)

MYALEPT should be administered once daily at the same time every day. MYALEPT can be administered any time of day without regard to the timing of meals.

Instruct patients that if a dose is missed, administer the dose as soon as noticed, and resume the normal dosing schedule the next day.

2.2 MYALEPT Preparation and Storage

Healthcare practitioners should provide proper training to patients and caregivers regarding how to prepare and administer the correct dose of MYALEPT prior to self-use. The patients and caregivers should prepare and administer the first dose of MYALEPT under the supervision of a qualified healthcare professional.

Instruct patients to store the vials of lyophilized powder in their carton in the refrigerator as soon as received [see How Supplied/Storage and Handling (16.2)].

MYALEPT can be reconstituted aseptically with 2.2 mL of sterile Bacteriostatic Water for Injection (BWFI), USP (0.9% benzyl alcohol), or with 2.2 mL of sterile Water for Injection (WFI).

When reconstituted in BWFI, MYALEPT solution can be used within 3 days when stored in the refrigerator between 36°F and 46°F (2°C and 8°C) and protected from light [see How Supplied/Storage and Handling (16.2)]. Discard unused reconstituted solution after 3 days. Attach the supplied sticker to the vial and enter the discard date.

For use in neonates and infants, reconstitute with preservative-free sterile WFI [see Warnings and Precautions (5.7) and Use in Specific Populations (8.4)]. When reconstituted in sterile WFI, MYALEPT should be administered immediately. Unused reconstituted solution cannot be saved for later use and should be discarded.

Reconstitution of the Lyophilized Powder

Instruct patients to follow the directions below for reconstitution of the lyophilized powder:

a)
Remove the vial containing the MYALEPT lyophilized powder from the refrigerator and allow the vial to warm to room temperature prior to use.
b)
Visually inspect the vial containing MYALEPT. The cake of lyophilized powder should be intact and white in color.
c)
Using a 3-mL syringe with a 22-gauge or smaller diameter needle withdraw 2.2 mL of sterile Bacteriostatic Water for Injection (BWFI) or preservative-free sterile Water for Injection (WFI). Do not reconstitute MYALEPT with other diluents.
d)
Inject the BWFI or WFI into the vial containing the lyophilized powder of MYALEPT, slowly injecting down the side of the vial. It is normal for some bubbles to form.
e)
Remove the needle and syringe from the vial and gently swirl the contents to reconstitute. Do not shake or vigorously agitate. When properly mixed, the MYALEPT reconstituted solution should be clear and free of clumps or dry powder, bubbles or foam. Do not use the solution if discolored or cloudy, or if particulate matter remains.
f)
Regarding the compatibility of MYALEPT reconstituted solution with other solutions:
  • Do not mix with, or transfer into, the contents of another vial of MYALEPT.
  • Do not add other medications, including insulin. Use a separate syringe for insulin injections.

See the MYALEPT Instructions for Use for complete administration instructions. The instructions can also be found at www.myalept.com.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.